IL2 and neoplasm: Several strategies have been developed to overcome the harmful side effects of IL-2-based therapy and to achieve better anti-tumor efficacy, e.g., introducing mutations into IL-2 fusion proteins affecting IL-2R subunit binding, and/or targeting IL-2 to tumor cells (14).